Cipla aims to achieve $1 billion sales in the US by the next fiscal year, driven by the products it has lined up for launch which the Indian drug maker expects will more than compensate for the imminent patent expiry and price erosion on cancer drug Revlimid. “We believe our pipeline should get us closer to the target (of $1 billion) or surpass that by FY27, depending on the launch timing,” managing director and global chief executive Umang Vohra said over an investor call on Friday.